Pharming Group (NASDAQ: PHAR) recently received a number of ratings updates from brokerages and research firms:
- 8/7/2026 – Pharming Group had its “sell (d)” rating reaffirmed by Weiss Ratings.
- 8/3/2026 – Pharming Group had its price target raised by Canaccord Genuity Group Inc. from $37.00 to $38.00. They now have a “buy” rating on the stock.
- 7/31/2026 – Pharming Group was downgraded by Zacks Research from “hold” to “strong sell”.
- 7/30/2026 – Pharming Group had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.
The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.
Featured Stories
- Five stocks we like better than Pharming Group
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Pharming Group NV Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group NV Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
